University of Pittsburgh researchers have developed the Integrated Proviral Sequencing Assay (IPSA), a novel technology that allows for the rapid amplification and identification of rare viral integration sites within the human genome. This assay is particularly significant for studying retroviruses such as HIV-1 and HIV-2, as well as other viral DNA genomes like hepatitis B virus and human herpes virus type 6. IPSA’s ability to amplify and sequence entire viral genomes, along with flanking host sequences, represents a major advancement in understanding viral integration and its implications for human health.
